Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

China flag China · Delayed Price · Currency is CNY
28.98
-1.42 (-4.67%)
Jun 1, 2026, 3:00 PM CST
Market Cap13.04B +58.2%
Revenue (ttm)745.32M +321.1%
Net Income-919.55M
EPS-2.31
Shares Out 445.54M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,182,658
Open30.78
Previous Close30.40
Day's Range28.91 - 31.44
52-Week Range22.40 - 63.59
Beta0.64
AnalystsStrong Buy
Price Target38.00 (+31.13%)
Earnings DateAug 28, 2026

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provide... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 1,325
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688062
Full Company Profile

Financial Performance

In 2025, SHA:688062's revenue was 662.52 million, an increase of 231.62% compared to the previous year's 199.78 million. Losses were -969.33 million, -7.14% less than in 2024.

Financial Statements